The addition of single dose GnRH agonist to luteal phase support in artificial cycle frozen embryo transfer: a randomized clinical trial.

Ye H, Luo X, Pei L, Li F, Li C, Chen Y, Zhang X, Huang G

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology31 Jan 2019Cited by 14 (Europe PMC)

PMID30700175DOI10.1080/09513590.2018.1563888PepBankPUB-30700175

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In artificial-cycle frozen embryo transfer, triptorelin did not significantly change implantation rates versus no supplementation.
In plain wordsTriptorelin did not significantly change implantation rates compared with no supplementation in frozen embryo transfer.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeImplantation rate
Study
n = 868
Comparator
No GnRHa supplementation
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg single dose · subcutaneous · day 3 after embryo transferAs given in this study (human).
Source sentences
Summary
There were no significant differences in terms of the rates of implantation, clinical pregnancy, ongoing pregnancy, and miscarriage between two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In conclusion, single dose of GnRHa (0.1 mg triptorelin acetate) supplementation 3 days after ET in AC-FET cycles did not show significant benefit on pregnancy outcomes as a whole.
Summary · context
A total of 868 FET cycles were included and randomized into two groups: Group A (n = 434) received GnRHa 0.1 mg subcutaneous injection on day 3 after embryo transfer (ET); Group B (n = 434) did not receive GnRHa.
Summary · context
The demographic characteristics, primary endpoint (implantation rate) and secondary endpoints (chemical pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate) were compared between two groups and subgroups (aged <35 years and 35-37 years).
Report a problemFND-3070017501
02HumanRandomized controlled trialEfficacy outcome
In women aged 35-37 years undergoing frozen embryo transfer, implantation was higher with triptorelin than control (45.3% versus 27.8%).
In plain wordsIn women aged 35-37 years, triptorelin increased implantation rates compared with control during frozen embryo transfer.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseImplantation rate in women aged 35-37 years
Study
n: not reported in source
Comparator
No GnRHa supplementation
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg single dose · subcutaneous · day 3 after embryo transferAs given in this study (human).
Measurements
Implantation rate
45.3%
GnRHa group aged 35-37 years
Implantation rate
27.8%
control aged 35-37 years
Source sentences
Summary
While, the subgroups analysis showed the implantation rate was significantly increased in advanced age women (35-37 years) in GnRHa group compared with control group (45.3% vs. 27.8%, p = .03).
3 context sentences(design, population, supporting numbers)
Summary · context
In conclusion, single dose of GnRHa (0.1 mg triptorelin acetate) supplementation 3 days after ET in AC-FET cycles did not show significant benefit on pregnancy outcomes as a whole.
Summary · context
A total of 868 FET cycles were included and randomized into two groups: Group A (n = 434) received GnRHa 0.1 mg subcutaneous injection on day 3 after embryo transfer (ET); Group B (n = 434) did not receive GnRHa.
Summary · context
The demographic characteristics, primary endpoint (implantation rate) and secondary endpoints (chemical pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate) were compared between two groups and subgroups (aged <35 years and 35-37 years).
Report a problemFND-3070017505
03HumanRandomized controlled trialEfficacy outcome
In artificial-cycle frozen embryo transfer, triptorelin did not significantly change clinical pregnancy rates versus no supplementation.
In plain wordsTriptorelin did not significantly change clinical pregnancy rates compared with no supplementation in frozen embryo transfer.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeClinical pregnancy rate
Study
n = 868
Comparator
No GnRHa supplementation
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg single dose · subcutaneous · day 3 after embryo transferAs given in this study (human).
Source sentences
Summary
There were no significant differences in terms of the rates of implantation, clinical pregnancy, ongoing pregnancy, and miscarriage between two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In conclusion, single dose of GnRHa (0.1 mg triptorelin acetate) supplementation 3 days after ET in AC-FET cycles did not show significant benefit on pregnancy outcomes as a whole.
Summary · context
A total of 868 FET cycles were included and randomized into two groups: Group A (n = 434) received GnRHa 0.1 mg subcutaneous injection on day 3 after embryo transfer (ET); Group B (n = 434) did not receive GnRHa.
Summary · context
The demographic characteristics, primary endpoint (implantation rate) and secondary endpoints (chemical pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate) were compared between two groups and subgroups (aged <35 years and 35-37 years).
Report a problemFND-3070017502
04HumanRandomized controlled trialEfficacy outcome
In artificial-cycle frozen embryo transfer, triptorelin did not significantly change ongoing pregnancy rates versus no supplementation.
In plain wordsTriptorelin did not significantly change ongoing pregnancy rates compared with no supplementation in frozen embryo transfer.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOngoing pregnancy rate
Study
n = 868
Comparator
No GnRHa supplementation
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg single dose · subcutaneous · day 3 after embryo transferAs given in this study (human).
Source sentences
Summary
There were no significant differences in terms of the rates of implantation, clinical pregnancy, ongoing pregnancy, and miscarriage between two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In conclusion, single dose of GnRHa (0.1 mg triptorelin acetate) supplementation 3 days after ET in AC-FET cycles did not show significant benefit on pregnancy outcomes as a whole.
Summary · context
A total of 868 FET cycles were included and randomized into two groups: Group A (n = 434) received GnRHa 0.1 mg subcutaneous injection on day 3 after embryo transfer (ET); Group B (n = 434) did not receive GnRHa.
Summary · context
The demographic characteristics, primary endpoint (implantation rate) and secondary endpoints (chemical pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate) were compared between two groups and subgroups (aged <35 years and 35-37 years).
Report a problemFND-3070017503
05HumanRandomized controlled trialSafety outcome
In artificial-cycle frozen embryo transfer, triptorelin did not significantly change miscarriage rates versus no supplementation.
In plain wordsTriptorelin did not significantly change miscarriage rates compared with no supplementation in frozen embryo transfer.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMiscarriage rate
Study
n = 868
Comparator
No GnRHa supplementation
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.1 mg single dose · subcutaneous · day 3 after embryo transferAs given in this study (human).
Source sentences
Summary
There were no significant differences in terms of the rates of implantation, clinical pregnancy, ongoing pregnancy, and miscarriage between two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In conclusion, single dose of GnRHa (0.1 mg triptorelin acetate) supplementation 3 days after ET in AC-FET cycles did not show significant benefit on pregnancy outcomes as a whole.
Summary · context
A total of 868 FET cycles were included and randomized into two groups: Group A (n = 434) received GnRHa 0.1 mg subcutaneous injection on day 3 after embryo transfer (ET); Group B (n = 434) did not receive GnRHa.
Summary · context
The demographic characteristics, primary endpoint (implantation rate) and secondary endpoints (chemical pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate) were compared between two groups and subgroups (aged <35 years and 35-37 years).
Report a problemFND-3070017504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT04174378

Luteal Phase Support In IVF Women Using GnRH Agonist

National University of Malaysian = 22229 Nov 2018 to 18 Nov 2019

IVF · Luteal Phase Defect

Trial page ClinicalTrials.govUpdated 25 Nov 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.